Semaglutide Reduces Severity of Common Liver Disease in People with HIV
March 5, 2024 -- A weekly injection of semaglutide was safe and reduced the amount of fat in the liver by 31% in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD), according to a presentation today at the 2024... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 5, 2024 Category: Pharmaceuticals Source Type: clinical trials

Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis Found Safe for HIV Prevention Throughout Pregnancy
March 5, 2024 -- The monthly dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine were each found to be safe for HIV prevention among cisgender women who started... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 5, 2024 Category: Pharmaceuticals Source Type: clinical trials

Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors
Conditions: Recurrent or Metastatic, Advanced Solid Tumors Interventions: Drug: IMB071703 injection Sponsors: Beijng Immunoah Pharma Tech Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants
Conditions: Chronic Spontaneous Urticaria Interventions: Biological: LP-003 Dose 1 (Single); Biological: LP-003 Dose 2 (Single); Biological: LP-003 Dose 3 (Single); Biological: LP-003 Dose 4 (Single); Biological: LP-003 Dose 5 (Single); Biological: Placebo (Single); Biological: LP-003 Dose 6 (Multiple); Biological: LP-003 Dose 7 (Multiple); Biological: LP-003 Dose 8 (Multiple); Biological: Placebo (Multiple) Sponsors: Longbio Pharma Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials

A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects
Conditions: Myelodysplastic Syndrome (MDS) Interventions: Biological: LP-001 Dose 1 (Single); Biological: LP-001 Dose 2 (Single); Biological: LP-001 Dose 3 (Single); Biological: LP-001 Dose 4 (Single); Biological: LP-001 Dose 5 (Single); Biological: LP-001 Dose 6 (Single); Biological: Placebo (Single); Biological: LP-001 Dose 7 (Multiple); Biological: LP-001 Dose 8 (Multiple); Biological: Placebo (Multiple) Sponsors: Longbio Pharma Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials

A Study Of TL-925 For The Treatment of AC
Conditions: Allergic Conjunctivitis Interventions: Drug: TL-925; Drug: Placebo Sponsors: Telios Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials

A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants
Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) Interventions: Biological: LP-005 Dose 1 (Single); Biological: LP-005 Dose 2 (Single); Biological: LP-005 Dose 3 (Single); Biological: LP-005 Dose 4 (Single); Biological: LP-005 Dose 5 (Single); Biological: LP-005 Dose 6 (Single); Biological: Placebo (Single); Biological: LP-005 Dose 7 (Multiple); Biological: LP-005 Dose 8 (Multiple); Biological: LP-005 Dose 9 (Multiple); Biological: Placebo (Multiple) Sponsors: Longbio Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Mar. 5, 2024-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 5, 2024 Category: Pharmaceuticals Source Type: clinical trials

NRx Pharmaceuticals Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
RADNOR, Pa., March 4, 2024. NRx Pharmaceuticals, Inc. ( " NRx Pharmaceuticals " , the " Company " ), a clinical-stage biopharmaceutical company, today announced that the 74th and last evaluable patient has completed their day 42 visit in its Phase 2b/3... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 4, 2024 Category: Pharmaceuticals Source Type: clinical trials

A Clinical Study With Adalimumab Biosimilar
Conditions: Pharmacokinetics; Safety Issues Interventions: Biological: Humira ® (adalimumab) AC Pen [Reference Product]; Biological: Adalimumab Richmond [Test Product] Sponsors: Laboratorios Richmond S.A.C.I.F.; FP Clinical Pharma S.R.L.; Custom Biologics Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials

SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
TEL AVIV, Israel, Feb. 29, 2024. SciSparc Ltd. ( " Company " or " SciSparc " ), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 29, 2024 Category: Pharmaceuticals Source Type: clinical trials

The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection.
Conditions: HPV Infection Interventions: Dietary Supplement: EGCG + folic acid + B12 Sponsors: Lo.Li.Pharma s.r.l Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials

Alpha Lipoic Acid in Pediatrics on Hemodialysis
Conditions: Hemodialysis Complication; Pediatric Kidney Disease; Cardiovascular Complication Interventions: Drug: Alpha lipoic acid; Other: Placebo Sponsors: Ain Shams University; Eva Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials

Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
Conditions: Interstitial Cystitis/Bladder Pain Syndrome Interventions: Drug: V117957; Drug: Placebo Sponsors: Imbrium Therapeutics; Purdue Pharma LP Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials

Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
BOSTON--(BUSINESS WIRE) February 29, 2024 -- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced positive topline results from its pivotal Phase III STARS trial, which evaluated the efficacy and safety of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 29, 2024 Category: Pharmaceuticals Source Type: clinical trials